Newsroom

GHENT, Bélgica--(BUSINESS WIRE)--A MRM Health, uma empresa biofarmacêutica em estágio clínico que desenvolve terapias para doenças imunomediadas, que exploram o poder do microbioma para restaurar o equilíbrio imunológico, anunciou hoje que o MH002, o principal candidato a Produto Bioterapêutico Vivo (LBP) racionalmente projetado da empresa, recebeu a designação de Fast Track da Food and Drug Administration (FDA) dos EUA para o tratamento da colite ulcerativa (CU) leve a moderada. O MH002 é atua...

LONDON--(BUSINESS WIRE)--  Xtrackers Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-119.899 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 30 April 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and tog...

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Multivariate analyses reveal that pCR is associated with transcriptomic differences and chemotherapy type, rather than self-reported race...

根特，比利时--(BUSINESS WIRE)--(美国商业资讯)-- MRM Health是一家专注于开发免疫介导性疾病治疗药物的临床阶段生物制药公司，致力于通过释放微生物组的潜力来恢复免疫平衡。该公司今日宣布，其首款理性设计的活体生物治疗产品（LBP）候选药物MH002，已获得美国食品药品监督管理局（FDA）授予的快速通道资格，用于治疗轻度至中度溃疡性结肠炎 (UC)。MH002目前是针对炎症性肠病（IBD）特异性机制研发最成熟的LBP，由六种特征明确的共生菌株经合理设计的微生物联合体组成。 FDA“快速通道”流程旨在促进药物研发，并加快对治疗严重疾病、满足未满足医疗需求的药物进行审查。其目的是让患者更早地获得重要药物。获得“快速通道”资格后，企业可与FDA保持频繁沟通，商讨药物研发计划，并确保收集到支持药物获批所需的适当数据。获得“快速通道”资格的产品还可能符合“加速批准”和“优先审评”的条件，且企业可分阶段提交新药申请（NDA）中已完成的章节。 ”FDA决定授予MH002快速通道资格，这表明这种前景光明的活体生物治疗产品有望满足溃疡性结肠炎患者对创新且更有效疗法的迫切需求——这...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Louisiana-Pacific Corporation declared a quarterly cash dividend of $0.30 per share to common stockholders of record as of May 14, 2026....

SEATTLE--(BUSINESS WIRE)--Cairn Surgical announced its pivotal trial met its primary endpoint, and reported a lower positive margin rate and reduced reexcisions versus control....

DALLAS--(BUSINESS WIRE)--Phelps welcomes five lawyers with an office in Uptown Dallas to support the business and litigation needs of financial services and corporate clients across Texas and the southwestern United States. With an established presence, the team comes from the former boutique, Johnston Clem Gifford, and brings commercial litigation experience to resolve sophisticated business disputes. This group of lawyers is known for advising banks, lenders and financial services companies a...

STAMFORD, Conn.--(BUSINESS WIRE)--ISG has launched a study examining providers that enable end-to-end, AI-enabled automation to coordinate complex workflows across enterprise systems....

ORANGE, Conn.--(BUSINESS WIRE)--Avangrid’s first of its kind event empowers the next generation of energy leaders to utilize artificial intelligence for solving business challenges...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: City of London Investment Management Company Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and...